ILF3: Difference between revisions
CSV import |
CSV import |
||
| Line 30: | Line 30: | ||
{{medicine-stub}} | {{medicine-stub}} | ||
{{No image}} | {{No image}} | ||
__NOINDEX__ | |||
Latest revision as of 14:30, 17 March 2025
ILF3 or Interleukin Enhancer Binding Factor 3 is a protein that in humans is encoded by the ILF3 gene. It is a double-stranded RNA (dsRNA) binding protein that associates with other proteins, dsRNAs, small noncoding RNAs, and mRNAs to regulate gene expression and stabilize mRNAs.
Function[edit]
ILF3 is a member of the nuclear factor of activated T-cells (NFAT) family. It is a part of a dimer that forms a complex with the protein NF45 (ILF2), which is involved in the regulation of gene expression in T lymphocytes. The proteins in this family are localized to the cytoplasm and the nucleus and are involved in the production of interleukin 2.
Clinical Significance[edit]
Alterations in the ILF3 gene have been associated with various diseases. For instance, it has been linked to cancer, where it is often overexpressed in cancerous cells. It has also been associated with autoimmune diseases, such as rheumatoid arthritis and lupus.
Research[edit]
Research into ILF3 is ongoing, with studies focusing on its role in the immune response, its potential as a therapeutic target in cancer treatment, and its involvement in autoimmune diseases.
See Also[edit]
References[edit]
<references />
